{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:12:21Z","timestamp":1789506741652,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,9,4]],"date-time":"2027-09-04T00:00:00Z","timestamp":1820016000000},"content-version":"am","delay-in-days":368,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002567","name":"American Academy of Allergy Asthma and Immunology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002567","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K23AI163350"],"award-info":[{"award-number":["K23AI163350"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtct.2026.02.063","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:31:43Z","timestamp":1773246703000},"page":"1111.e1-1111.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characterization of Hypogammaglobulinemia, Infection Incidence, and Mortality in Patients Receiving B-cell Maturation Antigen Chimeric Antigen Receptor (CAR) T-cell Therapy"],"prefix":"10.1016","volume":"32","author":[{"given":"Katherine J.","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2099-8974","authenticated-orcid":false,"given":"Baijun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2449-7831","authenticated-orcid":false,"given":"Joseph S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Pak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3623-7491","authenticated-orcid":false,"given":"Andrew J.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur S.","family":"Raje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frigault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-0393","authenticated-orcid":false,"given":"Marcela V.","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Barmettler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jtct.2026.02.063_bib0001","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-024-01191-8","article-title":"CAR-T cell therapy in multiple myeloma: current status and future challenges","volume":"14","author":"Swan","year":"2024","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.jtct.2026.02.063_bib0002","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Investig"},{"issue":"27","key":"10.1016\/j.jtct.2026.02.063_bib0003","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jtct.2026.02.063_bib0004","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.063_bib0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"25","key":"10.1016\/j.jtct.2026.02.063_bib0006","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.02.063_bib0007","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.jtct.2026.02.063_bib0008","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jtct.2026.02.063_bib0009","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.jtct.2026.02.063_bib0010","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1182\/bloodadvances.2021004603","article-title":"Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"5","author":"Wang","year":"2021","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.02.063_bib0011","doi-asserted-by":"crossref","first-page":"10073","DOI":"10.1182\/blood-2022-163733","article-title":"Infections and severe hypogammaglobulinemia in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"140","author":"Lancman","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2026.02.063_bib0012","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.jtct.2025.01.111","article-title":"Distinct patterns of pathogen-specific and non-specific immune reconstitution after CD19\/20- versus BCMA-targeted CAR-T cell therapy","volume":"31","author":"Krantz","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.063_bib0013","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/10408368909106589","article-title":"IgG subclass distribution in patients with multiple myeloma or with monoclonal gammopathy of undetermined significance","volume":"19","author":"Papadea","year":"1989","journal-title":"Ann Clin Lab Sci"},{"issue":"10","key":"10.1016\/j.jtct.2026.02.063_bib0014","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.4065\/80.10.1371","article-title":"Multiple myeloma: diagnosis and treatment","volume":"80","author":"Rajkumar","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jtct.2026.02.063_bib0015","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.2147\/OTT.S122241","article-title":"Non-secretory multiple myeloma: from biology to clinical management","volume":"9","author":"Dupuis","year":"2016","journal-title":"OncoTargets Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.063_bib0016","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2014","journal-title":"Haematologica"},{"issue":"15","key":"10.1016\/j.jtct.2026.02.063_bib0017","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.02.063_bib0018","unstructured":"International Myeloma Found International Myeloma Working Group (IMWG) uniform response criteria for multiple myeloma. International Myeloma Found.https:\/\/www.myeloma.org\/resource-library\/international-myeloma-working-group-imwg-uniform-response-criteria-multiple"},{"issue":"10","key":"10.1016\/j.jtct.2026.02.063_bib0019","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.clml.2023.05.008","article-title":"Recommendations for management of secondary antibody deficiency in multiple myeloma","volume":"23","author":"Giralt","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.jtct.2026.02.063_bib0020","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jaci.2024.10.021","article-title":"Association of CD19+-targeted chimeric antigen receptor (CAR) T-cell therapy with hypogammaglobulinemia, infection and mortality","volume":"155","author":"Sutherland","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.jtct.2026.02.063_bib0021","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/art.42620","article-title":"Comparative risks of infection with belimumab versus oral immunosuppressants in patients with nonrenal systemic lupus erythematosus","volume":"75","author":"Materne","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.jtct.2026.02.063_bib0022","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J ImmunoTher Cancer"},{"issue":"3","key":"10.1016\/j.jtct.2026.02.063_bib0023","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2026.02.063_bib0024","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.pathol.2021.02.002","article-title":"CAR-T cell therapy: practical guide to routine laboratory monitoring","volume":"53","author":"Selim","year":"2021","journal-title":"Pathology"},{"key":"10.1016\/j.jtct.2026.02.063_bib0025","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.tmrv.2009.09.011","article-title":"The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline","volume":"24","author":"Shehata","year":"2010","journal-title":"Transfus Med Rev"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.063_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cei\/uxac070","article-title":"British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy","volume":"210","author":"Grigoriadou","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jtct.2026.02.063_bib0027","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/cei.12493","article-title":"Immunoglobulin G treatment of secondary immunodeficiencies in the era of novel therapies","volume":"178","author":"Sepp\u00e4nen","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jtct.2026.02.063_bib0028","doi-asserted-by":"crossref","unstructured":"S Wijetilleka, C Mukhtyar, Jayne D, et al. Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: systematic literature review. 2019;18(5):535-41.","DOI":"10.1016\/j.autrev.2019.03.010"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726001818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726001818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:52:10Z","timestamp":1788987130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726001818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666636726001818"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.02.063","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of Hypogammaglobulinemia, Infection Incidence, and Mortality in Patients Receiving B-cell Maturation Antigen Chimeric Antigen Receptor (CAR) T-cell Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.02.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}